Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC24H24BrN5O4 |
InChIKeyBPLNOSFMIIASSJ-UXHICEINSA-N |
CAS Registry2921711-74-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Preclinical | CN | 25 Jan 2023 |